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Abstract
Background: There is emerging evidence that clinical and neuro-pathological manifestations of Huntington’s disease (HD) may occur in individuals with
intermediate length cytosine-adenine-guanine (CAG) repeats (27–35 CAG repeats) in the Huntingtin (HTT) gene. We aim to further define the clinical characteristics
of individuals who possess CAG repeat lengths in this range.
Methods: Data from the Cooperative Huntington’s Observational Research Trial (COHORT) were analyzed. Participants were categorized according to the
number of CAG repeats into normal (#26), intermediate (27–35) and HD (>36) groups. The motor, cognitive and behavioral scores on the Unified Huntington’s
Disease Rating Scale (UHDRS) were compared between the intermediate and normal groups.
Results: Of 1985 individuals affected by HD or with a family history of HD who were genotyped, 50 (2.5%) had their larger CAG repeat in the intermediate
range. There were statistically significant differences in scores of some motor, cognitive, and behavioral domains of UHDRS at baseline between normal and
intermediate length CAG repeats. Furthermore, a significantly greater number of subjects with CAG repeats in the intermediate range reported at least one suicide
attempt compared to the normal group.
Discussion: Our findings of motor, cognitive and behavioral abnormalities in individuals with intermediate CAG repeats suggest the presence of subtle, but
relevant, disease manifestations in patients with intermediate CAG repeats. These results have important implications for the pathogenesis of the disease and genetic
counseling.
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Introduction
Huntington’s disease (HD) is a progressive neurodegenerative
disease with a variable worldwide occurrence but the prevalence in
the United States is estimated at 7–10 in 100,000.1 Inherited in an
autosomal dominant manner, HD is caused by an expanded cytosine-
adenine-guanine (CAG) repeat length in the Huntingtin (HTT) gene on
chromosome 4p16.3, resulting in accumulation of mutant huntingtin
protein in the brain. While genetically defined HD requires> 36 CAG
repeats, some individuals with a mutable normal allele, or intermediate
CAG range (between 27 and 35 repeats), have been reported to exhibit
features of HD.2–6 Although most subjects with CAG repeats in this
range are normal, intermediate repeats have the potential to expand
into the disease range within one generation.7 In this study, we aim to
further define the clinical characteristics of patients who possess CAG
repeat lengths in the intermediate range as this has implications for
understanding of the pathogenesis of the disease and for genetic
counseling. We hypothesize that a subset of individuals with
intermediate alleles demonstrates subtle clinical manifestations that
resemble a mild HD phenotype. The expression of these features may
be related to other, currently unidentified, genetic and non-genetic
modifying factors.
Methods
Demographic, clinical and genetic data were analyzed, collected
from 45 centers in the United States, Canada and Australia that
participated in the Cooperative Huntington’s Observational Research
Trial (COHORT), a prospective observational study examining
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phenotypic characteristics and genetic factors in individuals from HD
families. The COHORT study involved a baseline visit comprising an
assessment with the Mini-Mental State Examination (MMSE), a
neurological and physical examination, including body mass index
(BMI), and the Unified Huntington’s Disease Rating Scale 99
(UHDRS 99), conducted by trained study personnel. The UHDRS
99 evaluated four domains, consisting of motor function, cognition,
behavior, and functional capacity. The motor assessment comprised
31 items, which included standardized ratings of chorea, dystonia,
oculomotor function, as well as a measure of diagnostic confidence,
defined as the degree to which the examiner was confident that the
subject met the definition of the unequivocal presence of an
extrapyramidal movement disorder in a subject at risk for HD.
Follow-up visits were conducted yearly, and included the UHDRS 99,
MMSE, a brief medical examination including height, weight and vital
signs, and any additional information with regard to medical or mental
health events. At each visit, subjects were also given the option of
participating in a family history questionnaire, and providing speci-
mens for storage in a repository. In order to maintain consistency, the
same individual for a particular subject performed the UHDRS from
year to year. Approval for COHORT was obtained from the
institutional review boards for human research.
Inclusion criteria for enrollment in the COHORT study included a
number of categories of subjects. Individuals were eligible to
participate if they had been clinically affected by HD or were positive
for the HD gene.8 Other subjects included in the COHORT were
those who had not undergone genetic testing but were first degree
relatives of an individual with manifest or pre-manifest HD, older
adolescents who had a parent with manifest HD or pre-manifest HD
enrolled in COHORT, or individuals who had not undergone DNA
testing but were grandparents or grandchildren of an individual
enrolled in COHORT who has manifest HD or pre-manifest HD.
Control subjects included spouses or caregivers of an individual
enrolled in COHORT with manifest HD or pre-manifest HD.
Individuals with a family history of HD who had undergone DNA
testing and did not carry the genetic mutation responsible for HD were
also included.
All CAG genotyping was performed on coded DNA samples at the
DNA Laboratory in the Molecular Neurogenetics Unit, Massachusetts
General Hospital. The CAG repeat lengths were determined based on
whole blood and lymphocyte analysis, and if both methods did not
yield the same result for a particular individual, testing was repeated
until the discrepancy was resolved and a common value was obtained.
The investigators and subjects did not have access to the results of
genotyping. The subjects were assessed yearly, for as many follow-up
visits as possible. Raters were blinded to the results of DNA genotyping
of the HTT gene. We report here baseline data collected through
December 31, 2009.
Study participants were assigned into three primary groups. Subjects
with an expanded CAG repeat length of 36 or more were classified
positive for HD, those with a CAG repeat of 27–35 were classified as
‘intermediate’, and those with less than 27 repeats were considered
‘normal’. Participant characteristics were compared across the three
primary groups using descriptive statistics. Initial analysis compared
differences in demographic and clinical metrics for the intermediate
versus normal and HD groups. Means were compared using analysis
of covariance models adjusted for age and gender, while proportions
were compared using Fisher’s exact tests.
Further analysis compared individual items from the motor and
behavioral sections of the UHDRS.9 These items are scored on a 0–4
point ordinal scale, with 0 representing no impairment and 1–4
representing increasing levels of impairment. For each item, the
distribution of scores was compared using a Wilcoxon rank sum test.
Comparisons were made between the intermediate and normal
groups. All hypothesis testing was conducted at the two-sided
significance level of 5%. No corrections were made for multiple
testing in this exploratory analysis.
Results
As of December 31, 2009, 2318 participants had enrolled in the
COHORT study. Information on CAG repeat length was not
available for 333 individuals and they were therefore excluded from
the analysis. Of the remaining 1985 subjects, 645 subjects were in the
normal range and 50 were in the intermediate range. Baseline
characteristics were assessed in the 1985 research participants
(Table 1). There were significantly more females in the intermediate
group than either the normal or the HD group. The level of education
did not differ between intermediate and HD subjects, but the
proportion employed and married were both significantly lower in
HD subjects. Baseline body mass index (BMI) was not significantly
different between the normal and intermediate group. Of note, a
significantly greater proportion of subjects in the intermediate group
reported at least one suicide attempt compared to the normal group.
In the motor component of the UHDRS, the intermediate group
had a significantly higher Total Maximal Dystonia Score (mean 0.01
vs 0.10, p50.001) compared with the control group. In addition,
compared with the normal group, there was a significantly lower
proportion of subjects in the intermediate group with normal scores in
the following categories: Vertical Saccade Velocity (89.8% vs 96.0%,
p50.05), Maximal Dystonia RUE (95.9% vs 99.5%, p50.004), and
Maximal Chorea LLE (95.9% vs 99.2%, p50.03). The items that were
significantly different are presented in Figure 1. Scores on the Stroop
Word Reading were lower in the intermediate group compared with
the normal group (mean 90.0 vs 95.7, p50.02). In the behavioral
domain, a lower proportion of subjects in the intermediate group
received normal scores in Depressed Mood – Severity (48.0% vs
61.8%, p50.02) and Suicidal Thoughts – Severity (96.0% vs 99.4%,
p50.01). There was a trend toward fewer intermediate subjects
scoring normally on Suicidal Thoughts – Frequency (96.0% vs 99.1%,
p50.05).
The UHDRS diagnostic confidence levels for each group are shown
in Figure 2. No differences in diagnostic confidence were detected
between the normal group and the intermediate (p50.86) group,
although there was a slightly higher proportion of subjects with
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Table 1. Demographic and UHDRS Data
Normal (N) Intermediate (I) p-value1 Huntington’s
Disease (HD)
p-value1
(n5645) (n550) (N vs. I) (n51290) (HD vs. I)
Age [years] 50.31 (13.29) 49.08 (13.13) 0.5828 48.80 (13.11) 0.8021
Female [%] 373 (57.8) 37 (74.0) 0.0256 708 (54.9) 0.0085
White [%] 602 (93.2) 48 (96.0) 0.7652 1206 (93.5) 0.7667
Employment status [% currently in labor
force]
444 (68.8) 36 (72.0) 0.7513 429 (31.6) ,0.0001
Marital status [% currently married] 505 (78.3) 40 (80.0) 0.8600 777 (60.2) 0.0047
History of at least one suicide attempt [%]
– Overall 9 (1.4) 3 (6.0) 0.0486 82 (6.4) 1.0000
– Females 7 (1.9) 3 (8.1) 0.0522 48 (6.8) 0.7346
– Males 2 (0.7) 0 (0) 1.0000 34 (5.8) 1.0000
Body mass index [kg/m2]
– Overall 28.63 (6.47) 28.67 (7.00) 0.8787 25.69 (5.42) 0.0003
– Females 28.28 (6.76) 28.91 (7.76) 0.5416 25.55 (6.07) 0.0008
– Males 29.09 (6.03) 28.01 (4.45) 0.5391 25.87 (4.50) 0.1823
Motor assessment
Total UHDRS motor assessment [0–124] 1.72 (2.91) 2.16 (3.14) 0.2581 30.11 (21.96) ,0.0001
Total maximal chorea score [0–28] 0.08 (0.41) 0.16 (0.59) 0.2245 7.72 (5.99) ,0.0001
Total maximal dystonia score [0–20]
– Overall 0.01 (0.14) 0.10 (0.42) 0.0014 2.64 (3.60) ,0.0001
– Females 0.02 (0.18) 0.14 (0.49) 0.0001 2.56 (3.64) ,0.0001
– Males 0.004 (0.06) 0 (0) 0.9178 2.74 (3.56) 0.0103
Behavioral assessment
UHDRS Behavioral frequency [0–44] 4.39 (4.33) 5.06 (4.48) 6.94 (6.25)
UHDRS Behavioral frequency x severity
[0–176]
6.27 (9.12) 8.28 (10.87) 0.1945 13.51 (15.87) 0.0186
Cognitive assessment
Mini Mental State Examination [0–30] 29.12 (1.51) 28.96 (1.56) 0.3783 26.01 (4.30) ,0.0001
UHDRS Verbal fluency 40.25 (11.84) 38.44 (11.51) 0.1612 26.43 (14.88) ,0.0001
UHDRS Symbol digit modalities test 47.35 (10.91) 45.65 (9.79) 0.0734 30.11 (15.28) ,0.0001
UHDRS Stroop color naming 74.60 (15.32) 72.27 (12.58) 0.1264 52.05 (20.86) ,0.0001
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confidence category of 2 and 4 in the intermediate group compared to
normal controls.
Discussion
HD presents with motor dysfunction as well as disturbances in
cognitive and behavioral domains. Historically, this disease has been
associated with stigma affecting not only patients with HD, but also
those who are at risk for developing HD.10 In recent years, several
cases have been reported in the literature, suggestive of clinical
manifestations of HD in individuals with intermediate CAG repeats, in
whom likely phenocopy syndromes have been excluded.11,12 This
observation, if confirmed, would have important implications for
genetic counseling.
In our analysis of the COHORT data, we found statistically
significant differences in some UHDRS scores between the normal and
intermediate group. These abnormalities tended to occur in some, but
not all, subjects with intermediate repeats. The findings draw attention
to the possibility of subtle motor, cognitive and behavioral abnorm-
alities in some subjects with intermediate CAG repeats, but the
differences that were identified in the motor scores would not likely be
clinically meaningful. Of potentially greater clinical significance was
that of the behavioral findings, including the history of suicide
attempts, which was comparable between the intermediate, and HD
groups. Whether this finding reflects an inherent abnormality in
subjects with intermediate CAG repeats, or a tendency that is
potentiated by the familial context, is unclear. Regardless, this finding
raises an area of interest for further studies, with possible relevance for
clinical management and intervention. The abnormal findings raise
the possibility of whether an intermediate length allele is indeed
sufficient to cause pathology, in a particular genetic and environmental
milieu. Thus, although relatively subtle, these abnormalities appear to
be important and relevant, particularly when they occur in the setting
of a family history of HD.
Table 1. Continued
Normal (N) Intermediate (I) p-value1 Huntington’s
Disease (HD)
p-value1
(n5645) (n550) (N vs. I) (n51290) (HD vs. I)
UHDRS Stroop word reading
– Overall 95.70 (18.36) 89.96 (16.67) 0.0187 67.39 (26.10) ,0.0001
– Females 96.90 (18.87) 88.19 (17.42) 0.0068 69.67 (26.00) ,0.0001
– Males 94.05 (17.53) 95.25 (13.46) 0.9647 64.66 (25.97) 0.0001
UHDRS Stroop interference 43.40 (13.35) 41.79 (11.59) 0.2201 30.43 (14.74) ,0.0001
UHDRS Independence assessment 99.83 (1.38) 99.49 (1.84) 0.0942 84.31 (16.47) ,0.0001
UHDRS Functional assessment 24.89 (1.05) 24.94 (0.32) 0.7427 20.31 (5.80) ,0.0001
UHDRS Total functional capacity 12.85 (0.76) 12.84 (0.59) 0.9021 9.31 (3.55) ,0.0001




Ocular Pursuit – Horizontal 0 (0–3) 0 (0–1) 0.9820 1 (0–4) ,0.0001
Ocular Pursuit – Vertical 0 (0–3) 0 (0–1) 0.9327 1 (0–4) ,0.0001
Saccade Initiation – Horizontal 0 (0–2) 0 (0–2) 0.1143 1 (0–4) ,0.0001
Saccade Initiation – Vertical 0 (0–2) 0 (0–1) 0.1788 1 (0–4) ,0.0001
Saccade Velocity – Horizontal 0 (0–1) 0 (0–1) 0.1096 1 (0–4) ,0.0001
Saccade Velocity – Vertical 0 (0–4) 0 (0–1) 0.0454 1 (0–4) ,0.0001
Abbreviations: N, Normal; I, Intermediate; HD, Huntington disease; n, sample size; UHDRS, Unified Huntington’s Disease Rating Scale.
UHDRS scores are listed as mean (standard deviation) unless otherwise noted.
1Two-sided p-values for comparing means based on Analysis of covariance (ANCOVA) model adjusted for age and gender; proportions compared using two-sided
Fisher’s exact test.
2Based on two-sided Wilcoxon test for comparing median score for Normals vs. Intermediates.
3Based on two-sided Wilcoxon test for comparing median score for Intermediates vs. HD.
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In this study population, the frequency of intermediate alleles was
2.5%, which is in the frequency range (up to 6%) reported in control
populations.13 Our figures do not include individuals whose larger
allele may have been in the HD range, as these were excluded from the
analysis. Hendricks et al. have estimated that the probability that a
male who is a ‘high normal’ carrier will have a risk of an offspring with
an expanded, penetrant, allele ranges from 1/6241 to 1/951.14 These
low estimates, however, have been derived from prevalence studies of
high normal alleles in the general population using a sample of
primarily Parkinson’s disease cases. Our results should be interpreted
with caution, particularly when comparing to the general population.
Data from this study were collected from subjects with signs or
symptoms suggestive of HD, or from family members, and should not
be applied to an otherwise healthy individual with similarly sized
alleles. An intermediate allele in a family with sporadic HD appears to
be less stable than those present in the general population.15
We acknowledge that there are a number of limitations to this study.
The differences that we identified between the normal and
intermediate groups may have occurred by chance as a result of
inter-rater variability, particularly if the distinction between normal
and mild impairment was based on the presence of subtle signs.
Although the UHDRS has a high rate of internal consistency within
each of the domains,9 and is considered the ‘gold standard’ in HD
clinical trials,16,17 the scale was originally designed for manifest
individuals, and therefore may not be as sensitive in early or mild
disease.18 The application of the UHDRS in the assessment of the
normal population is not well defined. Indeed, although we found that
a lower proportion of intermediate subjects scored normally on vertical
saccade velocity, we also note that the normal group included outliers
with very high scores, up to 4, which were not present in the
intermediate group (Table 1).
Given that the analysis was conducted in an exploratory nature,
adjustments for multiple comparisons were not applied. We do
acknowledge however that the presence of numerous data sets may
raise the possibility of a Type I error. A Bonferroni correction on all 84
hypothesis tests, consisting of 31 motor items, 25 behavioral items, and
28 demographic items, would establish a p-value of less than 0.0006 for
statistical significance. The significant findings in our study, however,
were all suggestive of abnormality in the intermediate group rather
than the normal group, and as such, the possibility of all of these
findings occurring by chance due to inter-rater variability in a blinded
setting would seem less likely.
We note that several relevant items such as mean diagnostic
confidence did not demonstrate significant differences, and we
postulate that this is related to the averaging effect in assessing mean
scores, in a population where only a minority of subjects appear to be
affected. Low BMI, which is described in prodromal individuals, was
also not found in our intermediate population. Whether the spectrum of
the intermediate phenotype has a tendency to overlap with gene-
expanded individuals in only certain areas is unclear. Weight loss in HD
has been shown to correlate directly with the CAG repeat length.19 The
eye movement abnormality identified in the intermediate group
Figure 1. Difference in Various UHDRS Items between Subjects with Normal
(,27) and Intermediate (27–35) CAG Repeats (0 5 Normal; 1–4 Represents
Increasing Levels of Impairment). *p,0.05, **p,0.01, RUE 5 right upper
extremity, LLE 5 left lower extremity
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consisted only of vertical saccade velocity, and no differences were seen
in ocular pursuit or saccadic initiation. Disturbances in eye motor
control appear to be associated with the degree of clinical severity,20
and this would be in keeping with the mild phenotype of the
intermediate group. Although further analysis stratified to gender
suggested that the total maximum dystonia score and UHDRS Stroop
Word Reading were due to the female intermediate subjects (Table 1),
the small numbers limit meaningful conclusions, and larger studies are
required.
Another limitation of our analysis is the lack of robust follow-up
data. Without the benefit of longitudinal assessment, disease onset may
potentially be missed, thus under-estimating the prevalence of
abnormal phenotypes. The relatively small number of subjects with
intermediate CAG repeats who attended follow-up visits does not
allow for meaningful interpretation of this component of data at this
time. Variations in age may have influenced the onset of disease. In
this study, however, we found no significant differences in age between
the normal, intermediate, and HD groups. In addition, our
comparison of means using analysis of covariance models was adjusted
for age.
The possibility of HD phenocopies must also be considered in an
individual with signs or symptoms suggestive of HD. Although
screening for HD phenocopies would have been valuable, in a study
population consisting of HD individuals and their family members, it is
unclear to what extent the possibility of HD phenocopies would have
accounted for the results. The possibility of laboratory error should
also be considered, particularly when interpreting alleles bordering on
different penetrance classes. In this study, all CAG genotyping was
performed in a single laboratory with considerable experience, on both
whole blood and lymphocytes. Despite these limitations, we believe
that the abnormal findings in the intermediate group are potential
areas of interest that warrant further evaluation. Additional studies
with larger sample sizes, follow-up assessments, and family data would
be valuable in further defining this population of subjects. In
Figure 2. Diagnostic Confidence at Baseline between the Normal, Intermediate, ‘High-Intermediate’ and HD Groups
Ha AD, Beck CA, Jankovic J Huntington’s Disease Intermediate CAG
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services6
conclusion, our exploratory analysis of the COHORT database
revealed statistically significant differences in many UHDRS scores
between normal and intermediate length CAG. Although not proven,
these findings support the concept that clinically manifest disease may
occur in individuals with intermediate CAG repeats.
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